Evidence map›Paper›PMID 22993174›Full record

ArticleJournal of clinical microbiology2012

Evaluation of the FTA carrier device for human papillomavirus testing in developing countries.

Paula Gonzalez, Bernal Cortes, Wim Quint, Aimée R Kreimer, Carolina Porras, Ana Cecilia Rodríguez, Silvia Jimenez, Rolando Herrero, Linda Struijk, Allan Hildesheim and 1 more

Open access · bronzeAbstract readComparative StudyEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 4 countries.

Paula GonzalezProyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica. pgonzalez@proyectoguanacaste.org
Bernal Cortes
Wim Quint
Aimée R Kreimer
Carolina Porras
Ana Cecilia Rodríguez
Silvia Jimenez
Rolando Herrero
Linda Struijk
Allan Hildesheim
Willem Melchers
Centre International de Recherche sur le Cancer · FRDDL Diagnostic Laboratory · NLGuanacaste Conservation Area · CRInstituto Costarricense de Investigación y Enseñanza en Nutrición y Salud · CRDivision of Cancer Epidemiology and GeneticsNational Cancer Institute · USRadboud University Nijmegen · NL

Funding

HPV Vaccine TrialZIACP010217 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI KREIMER, AIMEE · 2011 to 2025
$42.3M
NCI NIH HHS N01 CP011005
6 · The paper itself

Abstract

Liquid-based methods for the collection, transportation, and storage of cervical cells are cumbersome and expensive and involve laborious DNA extraction. An FTA cartridge is a solid carrier device, easier to handle and allowing simple DNA elution for human papillomavirus (HPV) testing. HPV-DNA results from cervical specimens collected in PreservCyt medium (Hologic, Inc.) and the indicating FTA elute cartridge were compared in an area where transportation and storage may affect the performance of the test. Cervical cells from 319 young adult women enrolled in the Costa Rica Vaccine Trial were collected by a nurse using a Cervex brush (Roberts), which was placed on the FTA cartridge and subsequently rinsed in 20 ml of PreservCyt medium. Two 0.5-ml PreservCyt aliquots were frozen for HPV-PCR testing; the FTA cartridges were kept at room temperature. HPV-DNA detection and typing was performed using SPF(10) PCR/DEIA (DNA enzyme immunoassay detection of amplimers)/LiPA(25) system. The percent agreement, agreement among positives, and kappas were estimated. Positivity was higher for FTA compared to PreservCyt specimens (54.5% versus 45.8%, P < 0.001). For oncogenic types, the overall agreement was 0.92, the agreement between positives was 0.74, and the kappa was 0.79. For individual HPV types, the overall agreement ranged from 0.97 to 1.00. We did not observe reduced cytology adequacy when specimen collection for cytology was preceded by FTA collection for HPV testing. HPV-DNA detection from FTA cartridges is broadly comparable to detection from PC medium. The higher HPV detection observed for FTA-collected specimens should be explored further. FTA cartridges could provide a simpler and more cost-effective method for cervical cell collection, storage, and transportation for HPV-DNA detection in research settings in developing countries.

Indexed as

AdultClinical Laboratory TechniquesCosta RicaDeveloping CountriesDNA, ViralEquipment and SuppliesFemaleGenotypeHumansPapillomaviridaePapillomavirus InfectionsSensitivity and SpecificitySpecimen HandlingVirologyYoung AdultDNA, Viral

Identifiers

PMID22993174
PMCPMC3503011
OpenAlexW1982904701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.